{"transactions":[{"id":2383644,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2022-02-23T00:54:37.000Z","date":"2022-02-18","kind":"other","acquired":true,"price":10000,"reported_value":10000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Convertible Notes were issued on February 18, 2022 in exchange of $10,000 in proceeds to the Company; have no stated maturity date or expiration date; bear interest at a simple rate equal to eight percent (8.0%) per annum until converted; and automatically convert into the same equity securities offered in the Qualified Financing (see footnote 2 and 3) or at the option of the holder into the same equity securities offered in a Smaller Financing (see footnote 2 and 3)."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F2","text":"Upon a Qualified Financing or Smaller Financing (see footnote 3), the conversion price shall be equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing (representing a 20% discount), or (ii) $1.00."},{"field":"valueOwnedAfter","element":"valueOwnedFollowingTransaction","label":"F3","text":"A Qualified Financing represents a single transaction or series or transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date of the Convertible Note (excluding proceeds from the issuance of any future Convertible Notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future Convertible Notes)."}],"derivative":{"underlying":"See footnotes"},"source":{"system":"sec-edgar","filing":"0001683168-22-001210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316822001210/ownership.xml","form_type":"4"}},{"id":2735107,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-04-30T19:58:00.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":5357,"price":2.8,"value":14999.6,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"RSU's granted under the 2020 Mosaic ImmunoEngineering Omnibus Incentive Plan as part of the reporting person's consulting agreement executed on April 29, 2021. RSUs will vest 100% on August 31, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date."}],"balance_after":5357,"derivative":{"exercise_date":"2022-08-31","underlying":"Common Stock","underlying_shares":5357},"source":{"system":"sec-edgar","filing":"0001683168-21-001650","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821001650/ownership.xml","form_type":"4"}},{"id":2891263,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":56000,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":570870},"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891262,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Series A Convertible Voting Preferred Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":161000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A Convertible Voting Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1641252},"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891261,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Common Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":570870,"ownership":{"direct":false,"nature":"By spouse."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":570870,"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}},{"id":2891260,"issuer":{"id":8636,"kind":"organization","name":"Mosaic ImmunoEngineering Inc."},"owners":[{"id":130165,"kind":"person","name":"Steinmetz Nicole Franziska","position":1,"cik":"0001822748","reported_name":"Steinmetz Nicole Franziska","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting CSO"}}],"security":"Common Stock","published_at":"2021-01-29T22:32:42.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":1641252,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Series A Convertible Voting Preferred Stock automatically converted for no additional consideration into 10.194106 shares of common stock on January 29, 2021, the date that both of the following criteria were met: (i) upon the Registrant having a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares of the Series A Convertible Voting Preferred Stock into common stock, which occurred on December 2, 2020 in conjunction with the reverse stock split; and (ii) the effectiveness of any registration statement registering the resale of the underlying shares of common stock of the Registrant, which occurred on January 29, 2021."}],"balance_after":1641252,"source":{"system":"sec-edgar","filing":"0001683168-21-000323","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/836564/000168316821000323/ownership.xml","form_type":"4"}}]}